Synthesis and evaluation of novel kinase inhibitors as anti-metastasis agents for
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EPIGEN BIOSCIENCES INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- L1EDVCGK2327
- Solicitation number
- PA13-088
- Topic code
- NCI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Methods for Nicotinic Receptor Modulation in the Treatment of Post-Operative Pain
- Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery
- New Therapy for the Treatment of Primary Biliary Cholangitis.
- Candidate selection of a LPAR1 antagonist for therapeutic application in NASH
- Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
25 SBIR/STTR records share this UEI (2012–2025). Reported award amounts total $20,235,589. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services